The study tested N-Nitrosodiethylamine (NDEA) in rats to compare dose-response relationships across three genotoxicity endpoints: gene mutation assays, error-corrected next-generation sequencing, and the alkaline comet assay.
In the News CISION PR Newswire – February 26, 2026 Scantox Acquires DuplexSeq Nonclinical Genomics Safety Business from TwinStrand Biosciences Read More
Kissy (Karen) Dabbs is an attorney with more than 20 years of experience in litigation, business development, and corporate representation. She most recently served as Associate General Counsel at CryoLife, Inc.
TwinStrand applies genomic technology across disciplines to improve human health and advance scientific discovery. Its mission is to develop and deliver Duplex Sequencing technology for applications in clinical medicine and life sciences.
A federal judge orders Guardant Health to pay more than $245 million to TwinStrand Biosciences and the University of Washington over infringement of patents covering Duplex Sequencing. The judgment includes $83.4 million in jury damages, $19.5 million in supplemental damages, $119.4 million in accrued royalties and $22.9 million in interest, and requires a 6% royalty on covered sales through March 2033. Guardant says collection will be stayed pending appeal and plans to challenge the ruling.
